Suppr超能文献

系统评价:粪便免疫化学检测和粪便隐血试验阳性与死亡率的关系。

Systematic review: Mortality associated with raised faecal immunochemical test and positive faecal occult blood results.

机构信息

Nottingham Colorectal Service, Nottingham University Hospitals NHS Trust, Queen's Medical Centre, Nottingham, UK.

National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, School of Medicine, Queen's Medical Centre, Nottingham, UK.

出版信息

Aliment Pharmacol Ther. 2024 Oct;60(7):840-854. doi: 10.1111/apt.18208. Epub 2024 Aug 20.

Abstract

BACKGROUND

Faecal haemoglobin (f-Hb) testing is used in colorectal cancer (CRC) screening and increasingly to guide the investigation in patients with symptoms suggestive of CRC. Studies have demonstrated increased mortality with raised f-Hb.

AIMS

To assess the association of raised f-Hb with all-cause, non-CRC (any cause excluding CRC) and cause-specific mortality.

METHODS

We searched Medline and Embase on 9 February 2024 to identify papers reporting mortality after faecal immunochemical (FIT) or guaiac faecal occult blood tests (gFOBT). The primary outcome was all-cause mortality following a positive compared to a negative test.

RESULTS

The search identified 3155 papers. Ten met the inclusion criteria: three reported gFOBT and seven reported FIT results, as screening tests. These reported a total of 14,687,625 f-Hb results. Elevated f-Hb was associated with an increased risk of all-cause, non-CRC and cause-specific mortality including death from cardiovascular, digestive and respiratory diseases. Crude risk ratios for all-cause mortality with a positive versus negative test were derived from six papers (three reporting gFOBT, three FIT). An increased risk was demonstrated in five, with RRs ranging from 1.11 (95% CI: 1.06-1.16) to 2.95 (95% CI: 2.85-3.05). For non-CRC mortality risk, RRs ranged from 1.09 (95% CI: 1.04-1.15) to 2.79 (95% CI: 2.70-2.89). We did not perform meta-analysis due to a limited number of papers reporting suitable results for each type of f-Hb test.

CONCLUSIONS

All-cause, non-CRC and cause-specific mortality appear higher in those with raised f-Hb. Population-based studies are warranted to elicit whether this association occurs in symptomatic patients.

摘要

背景

粪便血红蛋白(f-Hb)检测用于结直肠癌(CRC)筛查,并越来越多地用于指导有 CRC 症状的患者进行检查。研究表明,f-Hb 升高与死亡率增加有关。

目的

评估 f-Hb 升高与全因、非 CRC(CRC 以外的任何原因)和病因特异性死亡率的关系。

方法

我们于 2024 年 2 月 9 日在 Medline 和 Embase 上进行了检索,以确定报告粪便免疫化学(FIT)或愈创木脂粪便潜血试验(gFOBT)后死亡率的论文。主要结局是与阴性检测相比,阳性检测后的全因死亡率。

结果

检索到 3155 篇论文。符合纳入标准的有 10 篇:3 篇报告 gFOBT 结果,7 篇报告 FIT 结果,均为筛查试验。这些研究共报告了 14687625 例 f-Hb 结果。f-Hb 升高与全因、非 CRC 和病因特异性死亡率风险增加相关,包括心血管、消化和呼吸系统疾病导致的死亡。来自 6 篇论文(3 篇报告 gFOBT,3 篇 FIT)的粗全因死亡率风险比(RR)显示出阳性与阴性检测相比的风险增加。其中 5 项研究显示出增加的风险,RR 范围从 1.11(95%CI:1.06-1.16)到 2.95(95%CI:2.85-3.05)。非 CRC 死亡率风险的 RR 范围从 1.09(95%CI:1.04-1.15)到 2.79(95%CI:2.70-2.89)。由于每个 f-Hb 检测类型报告合适结果的论文数量有限,我们没有进行荟萃分析。

结论

f-Hb 升高者的全因、非 CRC 和病因特异性死亡率似乎更高。需要进行基于人群的研究,以确定这种相关性是否发生在有症状的患者中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验